{"transactions":[{"id":671099,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":9730,"price":49.13,"value":478034.9,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671098,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10350,"price":52.67,"value":545134.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671097,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12500,"price":40.29,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671096,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17500,"price":64.68,"value":1131900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671095,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2092,"price":83.09,"value":173824.28,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The transaction reported on this line reflects the cancellation in the Merger of options to purchase shares of Company Common Stock (each, a \"Company Stock Option\").  Immediately prior to the Effective Time, each Company Stock Option that was then outstanding but not vested became immediately vested in full. At the Effective Time, (i) each outstanding Company Stock Option having a per share exercise price less than the Merger Consideration was canceled and converted into the right to receive an amount in cash equal to the difference between the Merger Consideration and the applicable per share exercise price, less any applicable tax withholding, and (ii) any Company Stock Option having a per share exercise price equal to or greater than the Merger Consideration was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The transaction reported on this line reflects the cancellation in the Merger of Company Stock Options having a per share exercise price less than the Merger Consideration and the price reported in Column 8 represents the difference between the Merger Consideration and the applicable per share exercise price of the Company Stock Options."}],"balance_after":0,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":2092},"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671094,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5925,"price":85,"value":503625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction reported on this line reflects the cancellation in the Merger of restricted stock units of the Company (each, a \"Company RSU\"), each of which represented a contingent right to receive one share of the Issuer's Common Stock. Immediately prior to the Effective Time, each Company RSU that was then outstanding but not vested became immediately vested in full. At the Effective Time, each outstanding Company RSU was canceled and converted into the right to receive an amount in cash equal to the Merger Consideration, less any applicable tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":671093,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-09-01T21:01:10.000Z","date":"2026-09-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22836,"price":85,"value":1941060.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of July 6, 2026 (the \"Merger Agreement\"), by and among Crinetics Pharmaceuticals, Inc., a Delaware corporation (the \"Company\"), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (\"Parent\"), and Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), Merger Sub merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the \"Merger\"), effective as of September 1, 2026 (the \"Effective Time\"). At the Effective Time, each share of common stock of the Company, par value $0.001 per share (the \"Company Common Stock\"), issued and outstanding immediately prior to the Effective Time, except as provided in the Merger Agreement, was canceled and automatically converted into the right to receive $85.00 per share in cash, without interest and subject to any applicable tax withholdings (the \"Merger Consideration\")."}],"balance_after":5925,"source":{"system":"sec-edgar","filing":"0001628280-26-059902","document":"wk-form4_1788296467.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026059902/wk-form4_1788296467.xml","form_type":"4"}},{"id":730469,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-22T21:05:47.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":9730,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":9730,"derivative":{"exercise_price":35.87,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":9730},"source":{"system":"sec-edgar","filing":"0001628280-26-044717","document":"wk-form4_1782162344.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044717/wk-form4_1782162344.xml","form_type":"4"}},{"id":730468,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T21:05:47.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":5925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the\nfirst anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through\nsuch vesting date."}],"balance_after":28761,"source":{"system":"sec-edgar","filing":"0001628280-26-044717","document":"wk-form4_1782162344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000162828026044717/wk-form4_1782162344.xml","form_type":"4"}},{"id":741275,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-11T20:36:58.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 9, 2027 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":30188,"source":{"system":"sec-edgar","filing":"0000905148-26-002920","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000090514826002920/form4.xml","form_type":"4"}},{"id":758923,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-29T20:30:38.000Z","date":"2026-05-27","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 27, 2026 or (ii) immediately prior to the next Annual Meeting following May 27, 2026."}],"balance_after":80000,"derivative":{"exercise_price":1.86,"expiration_date":"2036-05-26","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001610717-26-000173","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071726000173/form4.xml","form_type":"4"}},{"id":774489,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-18T22:50:58.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":14058,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":14058,"derivative":{"exercise_price":25.8,"expiration_date":"2036-05-14","underlying":"Common Stock","underlying_shares":14058},"source":{"system":"sec-edgar","filing":"0001397266-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000139726626000002/ownership.xml","form_type":"4"}},{"id":774488,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T22:50:58.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":7751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 14, 2027."}],"balance_after":33696,"source":{"system":"sec-edgar","filing":"0001397266-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000139726626000002/ownership.xml","form_type":"4"}},{"id":1030539,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-09-30T20:41:34.000Z","date":"2025-09-26","kind":"exercise","planned":true,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/3rd of the options vested on February 16, 2019, and 1/36th of the options vested monthly thereafter."}],"balance_after":2092,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001658247-25-000010","document":"wk-form4_1759264890.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000010/wk-form4_1759264890.xml","form_type":"4"}},{"id":1030538,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-30T20:41:34.000Z","date":"2025-09-26","kind":"sale","planned":true,"acquired":false,"shares":16000,"price":44.75,"value":716000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the Reporting Person in open market transactions on the transaction date, with a sale price of $44.75 per share."}],"balance_after":22836,"source":{"system":"sec-edgar","filing":"0001658247-25-000010","document":"wk-form4_1759264890.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000010/wk-form4_1759264890.xml","form_type":"4"}},{"id":1030537,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-09-30T20:41:34.000Z","date":"2025-09-26","kind":"exercise","planned":true,"acquired":true,"shares":10000,"price":1.91,"value":19100.0,"ownership":{"direct":true},"balance_after":38836,"source":{"system":"sec-edgar","filing":"0001658247-25-000010","document":"wk-form4_1759264890.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000165824725000010/wk-form4_1759264890.xml","form_type":"4"}},{"id":1111620,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-06-13T20:30:17.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":10350,"derivative":{"exercise_price":32.33,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":10350},"source":{"system":"sec-edgar","filing":"0000950170-25-086266","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086266/ownership.xml","form_type":"4"}},{"id":1111619,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-13T20:30:17.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":6900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":28836,"source":{"system":"sec-edgar","filing":"0000950170-25-086266","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017025086266/ownership.xml","form_type":"4"}},{"id":1112979,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-06-13T00:39:27.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":7828,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024."}],"balance_after":18188,"source":{"system":"sec-edgar","filing":"0000905148-25-002141","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000090514825002141/form4.xml","form_type":"4"}},{"id":1129464,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025."}],"balance_after":80000,"derivative":{"exercise_price":0.72,"expiration_date":"2035-05-27","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129463,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":0.72,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129462,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":27802,"derivative":{"exercise_price":0.72,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129461,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"grant","planned":false,"acquired":true,"shares":85586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":85586,"derivative":{"exercise_price":0.72,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":85586},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129460,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129459,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1129458,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-30T22:30:51.000Z","date":"2025-05-28","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":1.69,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":85586},"source":{"system":"sec-edgar","filing":"0000950170-25-079925","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025079925/ownership.xml","form_type":"4"}},{"id":1142080,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-19T22:32:13.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":10787,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":10787,"derivative":{"exercise_price":34.84,"expiration_date":"2035-05-15","underlying":"Common Stock","underlying_shares":10787},"source":{"system":"sec-edgar","filing":"0000950170-25-074664","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017025074664/ownership.xml","form_type":"4"}},{"id":1142079,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-19T22:32:13.000Z","date":"2025-05-15","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) May 15, 2026."}],"balance_after":25945,"source":{"system":"sec-edgar","filing":"0000950170-25-074664","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017025074664/ownership.xml","form_type":"4"}},{"id":1264104,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":1.69,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1264103,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":27802,"derivative":{"exercise_price":1.69,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1264102,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"grant","planned":false,"acquired":true,"shares":85586,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Effective February 13, 2025, subject to and contingent on the approval by the Issuer's stockholders, the Board approved an option repricing with an exercise price of $1.69 per share (the \"Repricing\") of the outstanding stock options held by members of the Board, certain employees and other service providers, provided that if the requisite approval of the Issuer's stockholders is not obtained, the Repricing will be void and the terms of each repriced option shall continue to be subject to its original terms and conditions, including, without limitation, the per share exercise price. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":85586,"derivative":{"exercise_price":1.69,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":85586},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1264101,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":28571,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":0,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-13","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1264100,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27802,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17,"expiration_date":"2033-09-14","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1264099,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-18T21:30:06.000Z","date":"2025-02-13","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":85586,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On February 13, 2025, the Board approved the repricing of the option. As further described in footnote 4, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":2.51,"expiration_date":"2031-04-23","underlying":"Common Stock","underlying_shares":85586},"source":{"system":"sec-edgar","filing":"0000950170-25-022326","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000095017025022326/ownership.xml","form_type":"4"}},{"id":1384213,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":false,"shares":7844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":85586,"derivative":{"exercise_price":2.52,"expiration_date":"2031-04-22","underlying":"Common Stock","underlying_shares":7844},"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384212,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":false,"shares":6205,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.79,"expiration_date":"2030-09-07","underlying":"Common Stock","underlying_shares":6205},"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384211,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":2156,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":93430,"derivative":{"exercise_price":2.52,"expiration_date":"2031-04-22","underlying":"Common Stock","underlying_shares":2156},"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384210,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":6205,"derivative":{"exercise_price":8.79,"expiration_date":"2030-09-07","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384209,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":false,"shares":3783,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to the option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":8.32,"expiration_date":"2030-09-07","underlying":"Common Stock","underlying_shares":3783},"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384208,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":14049,"price":17.0346,"value":239319.0954,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades in prices ranging from $17.00 to $17.15, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":20100,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384207,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":true,"shares":7844,"price":2.52,"value":19766.88,"ownership":{"direct":true},"balance_after":34149,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384206,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-18","kind":"exercise","planned":true,"acquired":true,"shares":6205,"price":8.79,"value":54541.95,"ownership":{"direct":true},"balance_after":26305,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384205,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":7739,"price":17.0103,"value":131642.7117,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on May 10, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades in prices ranging from $17.00 to $17.045, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":20100,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384204,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":true,"shares":2156,"price":2.52,"value":5433.12,"ownership":{"direct":true},"balance_after":27839,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384203,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":true,"shares":1800,"price":8.79,"value":15822.0,"ownership":{"direct":true},"balance_after":25683,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1384202,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-10-18T22:25:19.000Z","date":"2024-10-17","kind":"exercise","planned":true,"acquired":true,"shares":3783,"price":8.32,"value":31474.56,"ownership":{"direct":true},"balance_after":23883,"source":{"system":"sec-edgar","filing":"0001610717-24-000511","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000511/form4.xml","form_type":"4"}},{"id":1472863,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T18:26:43.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":9900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025."}],"balance_after":9900,"derivative":{"exercise_price":37.42,"expiration_date":"2034-06-18","underlying":"Common Stock","underlying_shares":9900},"source":{"system":"sec-edgar","filing":"0000950170-24-075489","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017024075489/ownership.xml","form_type":"4"}},{"id":1472862,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-20T18:26:43.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":5345,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2023 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 18, 2025."}],"balance_after":20205,"source":{"system":"sec-edgar","filing":"0000950170-24-075489","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017024075489/ownership.xml","form_type":"4"}},{"id":1479374,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:13:15.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":28571,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"100% of the shares subject to the option shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":28571,"derivative":{"exercise_price":9.95,"expiration_date":"2034-06-12","underlying":"Common Stock","underlying_shares":28571},"source":{"system":"sec-edgar","filing":"0001610717-24-000335","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000335/form4.xml","form_type":"4"}},{"id":1479373,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-14T20:13:15.000Z","date":"2024-06-13","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Constitute restricted stock units (\"RSUs\") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the earlier of (i) one year anniversary of June 13, 2024 or (ii) immediately prior to the next Annual Meeting following June 13, 2024."}],"balance_after":20100,"source":{"system":"sec-edgar","filing":"0001610717-24-000335","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071724000335/form4.xml","form_type":"4"}},{"id":1483425,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-11T20:19:49.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":12500,"derivative":{"exercise_price":44.71,"expiration_date":"2034-06-07","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0000950170-24-071924","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071924/ownership.xml","form_type":"4"}},{"id":1483424,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-11T20:19:49.000Z","date":"2024-06-07","kind":"grant","planned":false,"acquired":true,"shares":3400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":21936,"source":{"system":"sec-edgar","filing":"0000950170-24-071924","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000095017024071924/ownership.xml","form_type":"4"}},{"id":1552848,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-04-02T22:13:10.000Z","date":"2024-03-31","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service."}],"balance_after":259000,"source":{"system":"sec-edgar","filing":"0000905148-24-001060","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000090514824001060/form4.xml","form_type":"4"}},{"id":1563349,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563348,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":20.23,"expiration_date":"2031-06-21","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563347,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":23.23,"expiration_date":"2030-06-18","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563346,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":0,"derivative":{"exercise_price":23.24,"expiration_date":"2029-06-20","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563345,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":17500,"price":45.5,"value":796250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":18536,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563344,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":18.29,"value":320075.0,"ownership":{"direct":true},"balance_after":36036,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563343,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":17500,"price":43.58,"value":762650.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":18536,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563342,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":17500,"price":20.23,"value":354025.0,"ownership":{"direct":true},"balance_after":36036,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563341,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":43.57,"value":544625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":18536,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563340,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":23.23,"value":290375.0,"ownership":{"direct":true},"balance_after":31036,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563339,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":43.57,"value":544625.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request."}],"balance_after":18536,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1563338,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-22T20:31:10.000Z","date":"2024-03-20","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":23.24,"value":290500.0,"ownership":{"direct":true},"balance_after":31036,"source":{"system":"sec-edgar","filing":"0001209191-24-005060","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919124005060/doc4.xml","form_type":"4"}},{"id":1583737,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T16:54:59.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":7500,"price":50.88,"value":381600.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":14860,"source":{"system":"sec-edgar","filing":"0000950170-24-029040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017024029040/ownership.xml","form_type":"4"}},{"id":1583736,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T16:54:59.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":2145,"price":50.85,"value":109073.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":22360,"source":{"system":"sec-edgar","filing":"0000950170-24-029040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017024029040/ownership.xml","form_type":"4"}},{"id":1583735,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-11T16:54:59.000Z","date":"2024-03-07","kind":"sale","planned":true,"acquired":false,"shares":2550,"price":50.89,"value":129769.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.53 to $51.78 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":24505,"source":{"system":"sec-edgar","filing":"0000950170-24-029040","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000095017024029040/ownership.xml","form_type":"4"}},{"id":1779112,"issuer":{"id":6115,"kind":"organization","name":"Neumora Therapeutics, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-09-18T21:51:37.000Z","date":"2023-09-14","kind":"grant","planned":false,"acquired":true,"shares":27802,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option shall vest and become exercisable on the date of the 2024 Annual Meeting, subject to the Reporting Person continuing in service on the Board through such vesting date."}],"balance_after":27802,"derivative":{"exercise_price":17,"expiration_date":"2033-09-13","underlying":"Common Stock","underlying_shares":27802},"source":{"system":"sec-edgar","filing":"0001610717-23-000282","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1885522/000161071723000282/form4.xml","form_type":"4"}},{"id":1847811,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-21T21:00:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":20.32,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-23-038819","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038819/doc4.xml","form_type":"4"}},{"id":1847810,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-21T21:00:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":18536,"source":{"system":"sec-edgar","filing":"0001209191-23-038819","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919123038819/doc4.xml","form_type":"4"}},{"id":1860152,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T18:32:21.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":7110,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024."}],"balance_after":7110,"derivative":{"exercise_price":51.82,"expiration_date":"2033-06-07","underlying":"Common Stock","underlying_shares":7110},"source":{"system":"sec-edgar","filing":"0001209191-23-035691","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919123035691/doc4.xml","form_type":"4"}},{"id":1860151,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T18:32:21.000Z","date":"2023-06-07","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3300,"price":51.82,"value":171006.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Shares were acquired upon the vesting of a previously reported RSU and were disposed of to permit the cash value of the awards to be credited to the deferred compensation plan account of the Reporting Person."}],"balance_after":27055,"source":{"system":"sec-edgar","filing":"0001209191-23-035691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919123035691/doc4.xml","form_type":"4"}},{"id":1860150,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-09T18:32:21.000Z","date":"2023-06-07","kind":"grant","planned":false,"acquired":true,"shares":3860,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 7, 2024."}],"balance_after":30355,"source":{"system":"sec-edgar","filing":"0001209191-23-035691","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919123035691/doc4.xml","form_type":"4"}},{"id":1869185,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2023-06-02T23:09:08.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":79500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":79500,"derivative":{"exercise_price":1.53,"expiration_date":"2033-05-30","underlying":"Common Stock","underlying_shares":79500},"source":{"system":"sec-edgar","filing":"0001140361-23-028152","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000114036123028152/form4.xml","form_type":"4"}},{"id":1869184,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-02T23:09:08.000Z","date":"2023-05-31","kind":"grant","planned":false,"acquired":true,"shares":57000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":109000,"source":{"system":"sec-edgar","filing":"0001140361-23-028152","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000114036123028152/form4.xml","form_type":"4"}},{"id":2206987,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2022-07-15T20:30:47.000Z","date":"2022-07-13","kind":"exercise","acquired":false,"shares":5700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017."}],"balance_after":0,"derivative":{"exercise_price":1.45,"expiration_date":"2027-11-05","underlying":"Common stock","underlying_shares":5700},"source":{"system":"sec-edgar","filing":"0001209191-22-042245","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122042245/doc4.xml","form_type":"4"}},{"id":2206986,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-15T20:30:47.000Z","date":"2022-07-13","kind":"sale","acquired":false,"shares":5700,"price":20.957,"value":119454.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of November 6, 2017."}],"balance_after":12536,"source":{"system":"sec-edgar","filing":"0001209191-22-042245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122042245/doc4.xml","form_type":"4"}},{"id":2206985,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-07-15T20:30:47.000Z","date":"2022-07-13","kind":"exercise","acquired":true,"shares":5700,"price":1.45,"value":8265.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":18236,"source":{"system":"sec-edgar","filing":"0001209191-22-042245","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122042245/doc4.xml","form_type":"4"}},{"id":2220015,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-28T17:52:23.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":6245,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023."}],"balance_after":6245,"derivative":{"exercise_price":60.57,"expiration_date":"2032-06-24","underlying":"Common Stock","underlying_shares":6245},"source":{"system":"sec-edgar","filing":"0001209191-22-039566","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919122039566/doc4.xml","form_type":"4"}},{"id":2220014,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-28T17:52:23.000Z","date":"2022-06-24","kind":"grant","acquired":true,"shares":3300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Award of Restricted Stock Units (\"RSUs\") under the Company's 2014 Incentive Plan. The RSUs shall vest in full on the earlier of (i) the Company's next Annual Meeting of Stockholders or (ii) June 24, 2023."}],"balance_after":26495,"source":{"system":"sec-edgar","filing":"0001209191-22-039566","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919122039566/doc4.xml","form_type":"4"}},{"id":2220928,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Non-Qualified Stock Option (Right to Buy)","published_at":"2022-06-27T20:48:29.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":31500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":31500,"derivative":{"exercise_price":7.35,"expiration_date":"2032-06-22","underlying":"Common Stock","underlying_shares":31500},"source":{"system":"sec-edgar","filing":"0001140361-22-024164","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000114036122024164/form4.xml","form_type":"4"}},{"id":2220927,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-06-27T20:48:29.000Z","date":"2022-06-23","kind":"grant","acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service."}],"balance_after":52000,"source":{"system":"sec-edgar","filing":"0001140361-22-024164","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000114036122024164/form4.xml","form_type":"4"}},{"id":2225434,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-21T20:46:11.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The entire number of shares subject to this option become fully vested and exercisable on the first to occur of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date."}],"balance_after":17500,"derivative":{"exercise_price":18.29,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-22-038438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919122038438/doc4.xml","form_type":"4"}},{"id":2343840,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-08T17:25:01.000Z","date":"2022-03-04","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vested in full on on June 18, 2015."}],"balance_after":0,"derivative":{"exercise_price":40.37,"expiration_date":"2024-07-10","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001209191-22-016930","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919122016930/doc4.xml","form_type":"4"}},{"id":2343839,"issuer":{"id":4337,"kind":"organization","name":"Ultragenyx Pharmaceutical Inc.","symbol":"RARE"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-03-08T17:25:01.000Z","date":"2022-03-04","kind":"exercise","acquired":true,"shares":7500,"price":40.37,"value":302775.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions."}],"balance_after":23195,"source":{"system":"sec-edgar","filing":"0001209191-22-016930","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000120919122016930/doc4.xml","form_type":"4"}},{"id":2522600,"issuer":{"id":6828,"kind":"organization","name":"Atara Biotherapeutics, Inc.","symbol":"ATRA"},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-05T20:28:37.000Z","date":"2021-11-04","kind":"sale","acquired":false,"shares":13354,"price":19.5,"value":260403.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction pursuant to Rule 10b5-1 Plan adopted May 14, 2021."}],"balance_after":31500,"source":{"system":"sec-edgar","filing":"0001567619-21-019403","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1397266/000156761921019403/doc1.xml","form_type":"4"}},{"id":2526320,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2021-11-03T20:55:44.000Z","date":"2021-11-01","kind":"exercise","acquired":false,"shares":8954,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":12092,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common stock","underlying_shares":8954},"source":{"system":"sec-edgar","filing":"0001209191-21-062728","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121062728/doc4.xml","form_type":"4"}},{"id":2526319,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:55:44.000Z","date":"2021-11-01","kind":"sale","acquired":false,"shares":8954,"price":25.5,"value":228327.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":12536,"source":{"system":"sec-edgar","filing":"0001209191-21-062728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121062728/doc4.xml","form_type":"4"}},{"id":2526318,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-03T20:55:44.000Z","date":"2021-11-01","kind":"exercise","acquired":true,"shares":8954,"price":1.91,"value":17102.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":21490,"source":{"system":"sec-edgar","filing":"0001209191-21-062728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121062728/doc4.xml","form_type":"4"}},{"id":2574800,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2021-09-09T21:00:37.000Z","date":"2021-09-08","kind":"exercise","acquired":false,"shares":6046,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":21046,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common stock","underlying_shares":6046},"source":{"system":"sec-edgar","filing":"0001209191-21-055314","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121055314/doc4.xml","form_type":"4"}},{"id":2574799,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-09T21:00:37.000Z","date":"2021-09-08","kind":"sale","acquired":false,"shares":6046,"price":25.5,"value":154173.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":12536,"source":{"system":"sec-edgar","filing":"0001209191-21-055314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121055314/doc4.xml","form_type":"4"}},{"id":2574798,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-09-09T21:00:37.000Z","date":"2021-09-08","kind":"exercise","acquired":true,"shares":6046,"price":1.91,"value":11547.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":18582,"source":{"system":"sec-edgar","filing":"0001209191-21-055314","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121055314/doc4.xml","form_type":"4"}},{"id":2623823,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2021-07-28T00:00:21.000Z","date":"2021-07-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":27092,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-048375","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121048375/doc4.xml","form_type":"4"}},{"id":2623822,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-28T00:00:21.000Z","date":"2021-07-26","kind":"sale","acquired":false,"shares":5000,"price":19.59,"value":97950.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.59. The range of sales prices on the transaction date was $19.53 to $20.00 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request."}],"balance_after":12536,"source":{"system":"sec-edgar","filing":"0001209191-21-048375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121048375/doc4.xml","form_type":"4"}},{"id":2623821,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-28T00:00:21.000Z","date":"2021-07-26","kind":"exercise","acquired":true,"shares":5000,"price":1.91,"value":9550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":17536,"source":{"system":"sec-edgar","filing":"0001209191-21-048375","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121048375/doc4.xml","form_type":"4"}},{"id":2629200,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2021-07-20T21:00:32.000Z","date":"2021-07-19","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":32092,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-047402","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121047402/doc4.xml","form_type":"4"}},{"id":2629199,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:00:32.000Z","date":"2021-07-19","kind":"sale","acquired":false,"shares":5000,"price":19.5,"value":97500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $19.50. The range of sales prices on the transaction date was $19.50 to $19.52 per share. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request."}],"balance_after":12536,"source":{"system":"sec-edgar","filing":"0001209191-21-047402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121047402/doc4.xml","form_type":"4"}},{"id":2629198,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-20T21:00:32.000Z","date":"2021-07-19","kind":"exercise","acquired":true,"shares":5000,"price":1.91,"value":9550.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."}],"balance_after":17536,"source":{"system":"sec-edgar","filing":"0001209191-21-047402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121047402/doc4.xml","form_type":"4"}},{"id":2634913,"issuer":{"id":3579,"kind":"organization","name":"Crinetics Pharmaceuticals, Inc."},"owners":[{"id":17933,"kind":"person","name":"Fust Matthew K","position":1,"cik":"0001397266","reported_name":"Fust Matthew K","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Non-qualified stock option (Right to Buy)","published_at":"2021-07-13T21:00:31.000Z","date":"2021-07-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 30 days prior to the trading date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock option granted March 17, 2018 with one-third vesting on the first anniversary of the grant date and the remainder vesting in a series of twenty-four (24) successive equal monthly installments thereafter."}],"balance_after":37092,"derivative":{"exercise_price":1.91,"expiration_date":"2028-03-16","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-21-046554","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658247/000120919121046554/doc4.xml","form_type":"4"}}],"next_cursor":"2021-07-13T21:00:31.000000Z,2634913"}